Biomea Fusion closed at $0.61 on Nov 4, down 1.91%, 72.3% below its 52-week closing high. Volume of 917.2K shares was 0.34× its 20-day average (below normal).
Split-adjusted performance: -51.0% over one month, -61.8% over six months, -53.6% over one year.
Short interest was 15.7M shares at the Oct 15 settlement, up 11.6% from the prior report (24.1% of float, 4.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BMEABiomea Fusion | $0.6119 | −1.91% | −61.8% | — | — | — | $44.4M | |
| ATNMActinium Pharmaceuticals | $1.41 | +0.71% | +13.7% | — | 79.7% | 3.9 | $44.3M | Compare |
| SERSerina Therapeutics | $1.69 | −7.65% | −7.7% | −100.0% | — | — | $42.9M | Compare |
| ELTXElicio Therapeutics | $1.56 | +2.63% | −85.1% | — | — | — | $42.3M | Compare |
| HYPDHyperion DeFi | $3.07 | +0.66% | −15.7% | — | 4009.1% | — | $46.7M | Compare |
| INMInMed Pharmaceuticals | $8.75 | +420.83% | +1104.6% | — | — | — | $48.1M | Compare |
| GANXGain Therapeutics | $1.11 | −3.48% | −41.9% | — | — | — | $48.4M | Compare |
| CNTBConnect Biopharma Holdings Limited | $0.7805 | +0.83% | −68.5% | +5666.7% | −624.4% | — | $49.2M | Compare |
| DWTXDogwood Therapeutics | $1.03 | −0.96% | −37.6% | — | — | — | $39.4M | Compare |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
